Blood markers to detect infected pancreatic necrosis
DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis
We will test whether specific blood markers can help predict or diagnose infected pancreatic necrosis in adults with necrotizing pancreatitis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 45 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Trial ID | NCT06899087 on ClinicalTrials.gov |
What this trial studies
This is an observational study enrolling adults with necrotizing pancreatitis confirmed by contrast-enhanced CT. Investigators will collect blood samples and clinical data over the course of care to look for circulating molecular signatures that distinguish infected pancreatic necrosis from sterile necrosis. Laboratory analyses will profile candidate biomarkers (for example inflammatory and infection-related proteins and nucleic acids) and correlate signatures with imaging, microbiology, and clinical outcomes. The goal is to develop a blood-based panel that could help identify infection earlier and more accurately than current methods.
Who should consider this trial
Good fit: Adults aged over 18 with necrotizing pancreatitis confirmed by contrast-enhanced CT who do not meet any exclusion criteria are the intended participants.
Not a fit: Patients with recurrent acute pancreatitis, pancreatic cancer, pregnancy or lactation, solid organ transplant, or immunodeficiency disorders are excluded and would not receive direct benefit from participating.
Why it matters
Potential benefit: If successful, this could enable earlier, less invasive detection of infected pancreatic necrosis and support timelier treatment to reduce complications and mortality.
How similar studies have performed: Prior work has identified candidate markers like procalcitonin and CRP with mixed results, so this study builds on partially successful, but still inconclusive, biomarker research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged \>18 years. * Diagnosis of NP based on CECT. Exclusion Criteria: * recurrent AP * pancreatic cancer * pregnancy, lactation * solid organ transplant * immunodeficiency disorders like AIDS.
Where this trial is running
Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Guru Trikudanatham, MD — University of Minnesota
- Study coordinator: Petr Vanek, MD, PhD
- Email: pvanek@umn.edu
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.